Indicaton
GI disorders
Debio 025 (alisporivir) is the first in a new class of drugs called cyclophilin inhibitors, with a potential in a wide range of therapeutic indications. Alisporivir was first thoroughly investigated for its antiviral properties in hepatitis C and HIV patients and consequently benefits from a large safety and efficacy database. Today, our development efforts are focused on non-viral diseases where cylophilins play a key role in regulating cell death pathways and we strive to generate compelling evidence supporting further clinical investigations in patients with high unmet medical needs.